MJA 222 9 19 May cover

Issues

Volume 222 Issue 9

19 May 2025

Cover image credit: Issara/stock.adobe.com

Editor's choice

From the MJA 19 May 2025 Free

General practice in the era of funding reform

How we fund our health system to achieve the most effective, efficient and equitable outcomes is high on the political agenda. Australia has just experienced a federal election dubbed “the health election” for one of the largest funding boosts to Medicare promised by both major parties.1 This issue of the MJA is dedicated to general practice — the bedrock of the health system that has arguably been in crisis for several years. A centrepiece of Labor's campaign on health was a pledge to build more bulk‐billing urgent care centres around the country. These centres aim to bridge the gap for urgent illnesses when patients cannot see their general practitioner and reduce pressure on emergency departments (EDs).2 In this issue of the MJA, Savira and colleagues3 conducted a scoping review to examine the effectiveness of urgent care centres. They examined studies conducted in clinics in the UK, Europe and the United States and found that the results with respect to reduction in ED visits were mixed. While some studies reported that the introduction of these clinics was associated with a reduction in ED visits, others often showed no changes or an increase in presentation to ED minor injury units. Importantly, most studies examined showed a reduction in hospital admission rates in places where urgent care clinics had been set up. Although most patients in consumer surveys examined were happy with the service, continuity of care was a concern expressed by both patients and practitioners. Even though the review was limited by the high heterogeneity of methodologies examined, it provides a warning about relying on a model without adequate governance and formal assessment of cost effectiveness. Indeed, a recent interim report by the Department of Health and Aged Care found that although the cost of seeing a doctor in an urgent care clinic is lower than in an emergency department, this cost is at least five times that of seeing a general practitioner for a standard consult.4 Continuity of care has been an ongoing issue in primary health care for several years. Unlike the UK and New Zealand, where patients are often enrolled into their local primary care clinics for care, in Australia most people can visit any general practitioner anywhere for care, which often leads to a significant amount of fragmentation of care and over ordering of investigations.5 The MyMedicare initiative that has been recently rolled out in Australia attempts to correct this. Bates and colleagues6 in their scoping review for this issue examined enrolment models in other countries to elucidate their impacts on continuity of care. They found little evidence that enrolment improved continuity of care; however, study populations had high levels of pre‐existing patient engagement with a usual general practitioner The review provided evidence that enrolment can be used to support other primary care reforms such as preventive care and management of chronic conditions, and demonstrated how other reforms, such as incentives or increased access to services, can affect uptake of enrolment. For MyMedicare to work, practices and patients need to see value in enrolment. This value proposition will be hard to make without more targeted research evaluating, and then demonstrating, the benefits of enrolment, not just for individuals who have a usual general practitioner, but for those who do not. Although the review noted that the MyMedicare scheme currently has limited incentives for patients, there have been proposals to tie in funding for chronic care plans and allied health visits to a patient's nominated general practitioner and practice on MyMedicare.7 This will likely pressure general clinics to enrol patients specifically to their clinics. The overarching problem most general practitioners have with investment in primary care is that often the governments do not seem to want to consult with them with regards to their experiences and opinions on how unprecedented levels of Medicare funding might best suit their patients. Most clinics currently run on the slimmest of margins and the bulk‐billing incentive still does not meet the gap that mixed billing currently provides most clinics.8 Without effective primary care most Australians will be left without adequate health care. A substantial proportion of research needs to be carried out on effective models of care focusing on general practitioners with general practitioners as a core part of the research and assessment team.

Aajuli Shukla

Perspective

Pharmacology 5 May 2025 Open Access

Antidepressant prescribing in Australian primary care: time to reevaluate

Given limited benefit in mild to moderate mental illness, limited evidence demonstrating benefit and safety with long term antidepressant therapy, and the difficulties that people can experience stopping antidepressants, better decision support and informed consent for starting antidepressants are needed

Katharine A Wallis · Anna King · Joanna Moncrieff

Medical education

Erratum

19 May 2025 Free

Erratum

Hengel B, Guy RJ, Casey D, et al. Decentralised COVID‐19 molecular point‐of‐care testing: lessons from implementing a primary care‐based network in remote Australian communities. Med J Aust 2025 ; https://doi.org/10.5694/mja2.52589. In this perspective article, the middle initial of the seventh author was incorrect; it should read Tanya L Applegate.

Reflection

General medicine 19 May 2025 Free

I am a Civil War

This is an article written by a doctor about their experience of navigating seronegative immune-mediated necrotising myositis

Jennifer G Mowbray

Editorial

Research

Women's health 5 May 2025 Open Access

The prevalence of intimate partner violence in Australia: a national survey

The lifetime prevalence of experiencing intimate partner violence is high, especially among women

Ben Mathews · Kelsey L Hegarty · Harriet L MacMillan · Monica Madzoska · Holly E Erskine · Rosana Pacella · James G Scott · Hannah Thomas · Franziska Meinck · Daryl Higgins · David M Lawrence · Divna Haslam · Sara Roetman · Eva Malacova · Timothy Cubitt

Scoping review

Guideline summary

Musculoskeletal diseases 28 April 2025 Open Access

2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age

Poor bone health is highly treatable with appropriate widely available lifestyle and dietary measures and pharmacological agents; the updated guideline is an evidence-based pragmatic tool to assist general practitioners in the day-to-day care of such patients in partnership with bone specialists

Peter Wong · Weiwen Chen · Dan Ewald · Christian Girgis · Morton Rawlin · John Tsingos · Justine Waters

News

Vaccination 23 May 2025 Media release Free

New vaccines herald “era-defining advancements” in RSV prevention

A narrative review published in the Medical Journal of Australia examines the current landscape and future directions of respiratory syncytial virus (RSV) preventives in Australia. RSV is a major cause of acute lower respiratory tract infections, and disproportionally impacts children under the age of 4, who represent 50% of RSV hospitalisations. In November 2023, the long-acting monoclonal antibody nirsevimab was registered with the Therapeutic Goods Administration (TGA) for prevention of RSV-related infections in children under two years of age. Shortly after, in March 2024, a maternal RSV vaccine, Abrysvo, was registered with the TGA for prevention of RSV-related infections in infants under 6 months of age. The narrative review authors describe the availability of these vaccines as “an era defining advancement in RSV prevention.” “Both nirsevimab and Abrysvo have demonstrated substantial potential in reducing hospitalisation rates and mitigating long term health care costs associated with RSV infections in infants,” Sam Barnett of Monash University and co-authors wrote. Western Australia leading the charge at home Western Australia was the first Australian jurisdiction to announce a state-wide immunisation program, rolling out a government funded all-infant RSV immunisation program with nirsevimab in April 2024. A research letter published in the Medical Journal of Australia has examined the impact that the immunisation program had on the WA health care system. “From 2 April 2024, all WA infants born during 1 October 2023 – 30 September 2024 were eligible to receive nirsevimab in primary care services and birthing hospitals, as were Aboriginal children and children with conditions associated with severe RSV disease born during 1 October 2022 – 30 September 2023,” Dr Lauren Bloomfield and co-authors wrote. “With 71% of nirsevimab-eligible infants receiving RSV prophylaxis during April–September 2024, the number of RSV-associated hospitalisations in WA was 57% lower than expected during May–December 2024, equivalent to one hospitalisation averted per 43 infants immunised.” “Further, a contemporary case–control study found that nirsevimab was 86.4% effective in averting RSV-associated hospitalisations of infants in WA. As the cost of an infant RSV hospital admission is estimated to be $12 346 to $13 695, averting 505 admissions is likely to have saved $6.2–6.9 million in hospital costs.” The future of RSV prevention In 2025, Australia has a national RSV prevention program with free maternal vaccination with Abrysvo and targeted infant protection with nirsevimab. Analysing the data from this national program will be pivotal in evaluating and refining the national RSV prevention response going forward. “Program monitoring and evaluation, including cost-effectiveness modelling, from the 2025 RSV [Mother and Infant Protection Program] MIPPs will help guide future decisions regarding the optimal combination of maternal vaccination and nirsevimab,” Barnett and co-authors wrote in their narrative review. “These studies, which will incorporate Australian-specific data, will evaluate factors such as cost-effectiveness, timing, geographic variability and logistical considerations in relation to administration.” Successful implementation of RSV prevention programs will depend on maintaining cost effectiveness, addressing parental acceptance and uptake of the vaccines, and ensuring accessibility for groups at increased risk, such as First Nations children. “An evidence-based approach will be essential to ensure appropriate allocation of resources, tailoring programs to the specific needs of higher risk populations while maximising the economic and health benefits across Australia,” Barnett and co-authors wrote. Read the narrative review in the Medical Journal of Australia. Read the research letter in the Medical Journal of Australia.

Annika Howells

Next Issue Volume 222 Issue 10

View more
MJA 222 10 2 Jun cover
Editor’s choice 2 June 2025 Free

Exploring non‐communicable diseases in Australian communities

Wendy Morgan

Perspective 19 May 2025 Open Access

Shifting focus to adolescent wellbeing and inclusive participation in the digital age

with the Health Advisory Panel for Youth at the University of Sydney (HAPYUS)

Perspective 12 May 2025 Free

Preparing Australia for future pandemics: strengthening trust, social capital and resilience

Shanti Narayanasamy · Alisa Pedrana · Katherine B Gibney · Lisa Gibbs · Margaret E Hellard

Perspective 2 June 2025 Open Access

National Framework for Prevocational Medical Training

Brendan Crotty · Nicholas J Glasgow · Jo Burnand · Georga Cooke · Katrina Anderson · Kirsty White · Sarah Vaughan · Madeleine Novak · Andrew H Singer

Previous Issue Volume 222 Issue 8

View more
MJA 222 8 5 May cover
Editor’s choice 5 May 2025 Free

What's past is prologue

Michael Skilton

Perspective 7 April 2025 Open Access

The potential of maternal and child health service data in Australia: how lessons from the COVID‐19 pandemic can accelerate data‐informed decision making

Ashleigh Shipton · Meredith O'Connor · Melissa Wake · Sharon Goldfeld · Helen Lees · Catina Adams · Kristina Edvardsson · Leesa Hooker · Jatender Mohal · Rhiannon M Pilkington · Fiona K Mensah

Perspective 5 May 2025 Open Access

Exploring the role of urine drug screening in opioid agonist therapy

Grace FitzGerald · Sione Crawford · Adrian J Dunlop · Jon Cook · Dean Membrey · Paul MacCartney · Thileepan Naren

Perspective 17 March 2025 Open Access

Cultural safety, the LGBTQI+ community and international medical graduate training

Cindy Towns · Charlene Rapsey · Rhea Liang

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.